Cysteinyl-leukotriene1 receptor is a potent target for the prevention and treatment of human urological cancer

Molecular Medicine Reports

Volumn 3, Issue 2, 2010, Pages 245-251

  Matsuyama, Masahide ^a   Yoshimura, Rikio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Cysteinyl leukotriene1 receptor; Cysteinyl leukotriene1 receptor antagonist; Prostate cancer; Renal cell carcinoma; Testicular cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYSTEINYL LEUKOTRIENE 1 RECEPTOR; HOE 33342; LEUKOTRIENE RECEPTOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER PREVENTION; CANCER THERAPY; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TESTIS CANCER; URINARY TRACT CANCER;

EID: 77950818399     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000247     Document Type: Article

References (25)

1. Oh WK and Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160: 1220-1229, 1998. (Pubitemid 29480485)
2. Weidner N, Folkman J, Pozza F, Bevilaqua P, Allred EN and Moore DH: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage brest carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992. (Pubitemid 23004615)
3. Lafyatis R, Thompson NL , Remmers EF, Flanders KC , Roche N NS and Kim SJ: Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. J Immunol 143: 1142-1148, 1989. (Pubitemid 19211338)
4. Yoshimura R, Matsuyama M, Kawahito Y, et al: Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med 13: 229-233, 2004.
5. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J and Wada S: Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 165: 1468-1472, 2001. (Pubitemid 32410216)
6. Yoshimura R, Sano H, Masuda C, et al: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589-596, 2000. (Pubitemid 30640105)
7. Hase T, Yoshimura R, Matsuyama M, et al: Cyclooxygenase-1 and -2 in human testicular tumours. Eur J Cancer 39: 2043-2049, 2003. (Pubitemid 37297761)
8. Matsuyama M, Yoshimura R, Mitsuhashi M, et al: 5-lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 14: 73-79, 2005.
9. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H and Nakatani T: Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 170: 1994-1999, 2003. (Pubitemid 37254995)
10. Matsuyama M, Yoshimura R, Mitsuhashi M, et al: Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 24: 821-827, 2004.
11. Yoshimura R, Matsuyama M, Mitsuhashi M, et al: Relationship between lipoxygenase and human testicular cancer. Int J Mol Med 13: 389-393, 2004.
12. Lynch KR , O'Neill GP, Liu G, et al: Characterization of human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789-793, 1999.
13. Ohd JF, Wikstrom K and Sjolander A: Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 119: 1007-1018, 2000.
14. Nielsen CK , Campbell JI, Ohd JF, et al: A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 65: 732-742, 2005.
15. 1 receptor in human renal cell carcinima. Mol Med Rep 1: 185-189, 2008.
16. 1 receptor and human transitional cell carcinoma in bladder. Urology 73: 916-921, 2009.
17. 1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep 18: 99-104, 2007.
18. 1 receptor in human testicular cancer and growth reduction by its antagonist through apoptosis. Mol Med Rep 2: 163-167, 2009.
19. Sano H, Hla T, Maier JAM, et al: In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 89: 97-108, 1992.
20. Fitzgerald SM and Flinn S: Evaluating research studies using the analysis of variance (ANOVA): issues and interpretations. J Hand Ther 13: 56-60, 2000. (Pubitemid 30134138)
21. Storms W: Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opin Pharmacother 8: 2173-2187, 2007. (Pubitemid 47505591)
22. Horwitz RJ, McGill KA and Busse WW: The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 157: 1363-1371, 1998. (Pubitemid 28242064)
23. Wenzel SE: New approaches to anti-inflammatory therapy for asthma. Am J Med 104: 287-300, 1998. (Pubitemid 28163174)
24. Drazen J: Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am J Respir Crit Care Med 157: 233-237, 1998. (Pubitemid 28304149)
25. Matsuyama M, Yoshimura R, Tsuchida K, et al: Lipoxygenase inhibitors prevent urological cancer cell growth. Int J Mol Med 13: 665-668, 2004.